CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 33 enrolled
Drug / intervention
Feedback +1 morebehavioral
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03533660
NCT03533660N/ACompleted
CompareCT.gov

Alcohol Biosensor Monitoring for Alcoholic Liver Disease

University of Pittsburgh·interventional·Posted May 23, 2018·Updated Nov 7, 2022

In Brief

A clinical study evaluating Feedback and Enhanced Usual Care for Alcohol Use, Unspecified. Completed, enrolled 33 participants across 1 site.

Detailed Summary

Successful treatment of alcohol associated liver disease (AALD) depends primarily on abstinence from alcohol. The investigators propose a randomized clinical trial of alcohol biosensor monitoring for patients with alcohol associated liver disease to determine if monitoring with feedback on alcohol use patterns reduces alcohol consumption and improves outcomes.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAlcohol Use, Unspecified
CountriesUnited States
CollaboratorsNational Institute on Alcohol Abuse and Alcoholism (NIAAA)

Timeline

N/ACompletedFinished
20192020202120222023202420252026
First PostedMay 23, 2018
Enrollment StartSep 13, 2018
Primary CompletionFeb 28, 2021
Study CompletionJun 28, 2021
TodayJul 2, 2026
Enrollment to primary: 2.5 yearsPosted 8.1 years ago

Interventions

Feedbackbehavioral

Participant will receive a brief feedback on alcohol use data downloaded from the ABM and information about treatment resources

Enhanced Usual Carebehavioral

Participant will receive information on self reported alcohol use and information about remaining abstinent and about treatment resources